United Therapeutics Corporation

UTHRleader

United Therapeutics focuses on life-saving treatments for pulmonary arterial hypertension and is pioneering xenotransplantation — using genetically modified pig organs for human transplant. It has over $5B in cash and no long-term debt.

⇄ Compare

Products & Revenue

Product Revenue Share

Revenue Breakdown ($2.8B)

Static data (loading live financials…)

Tyvaso Products (55%)

Remodulin (25%)

Orenitram (12%)

Other (8%)

Segment Breakdown & Key Customers

Product Details

Tyvaso / Tyvaso DPI (Inhaled Treprostinil)55%

Pulmonary arterial hypertension (PAH) + pulmonary hypertension associated with ILD. Fastest-growing drug.

Remodulin (Treprostinil Infusion)25%

Continuous subcutaneous/IV infusion for severe PAH.

Orenitram (Oral Treprostinil)10%

Oral extended-release treprostinil for PAH.

Unituxin / Transplant Pipeline10%

Pediatric neuroblastoma + regenerative medicine (xenotransplantation organs).

Supply Chain Relationships

Macro & Market Context

헬스케어Sector News

메디케어 수가 압박 vs AI 진단 효율화 — 선별적 접근 필요

미국 헬스케어 지출 (2026E)

$4.8T

AI 진단 정확도 개선

+23% vs 기존

UNH 의료손해율

87.3%

약가 협상 대상 의약품

20종 (IRA)

Upcoming Catalysts

◆CMS 메디케어 최종 수가 발표 (2026.Q2)◆UNH/HUM/CVS Q1 실적 (2026.04)◆IRA 약가 협상 2차 품목 공개

Latest News

Loading news...

AI Analysis

Click "Get AI Analysis" for an AI-powered supply chain analysis of United Therapeutics Corporation.

Company Info

Headquarters

Silver Spring, MD

Founded

1996

Employees

2,600

Website

unither.com

Sector Overview — 헬스케어

Sector News